Balyasny Asset Management
SYRE icon

Balyasny Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Balyasny Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1M Buy
147,042
+91,565
+165% +$6.68M 0.02% 938
2026
Q1 		$2.8M Sell
55,477
-17,988
-24% -$678K ﹤0.01% 1631
2025
Q4 		$2.41M Buy
+73,465
New +$1.92M ﹤0.01% 1769
2024
Q4 		– Sell
-227,950
Closed -$6.7M – 3250
2024
Q3 		$6.7M Sell
227,950
-44,686
-16% -$1.24M 0.01% 1144
2024
Q2 		$6.41M Buy
272,636
+240,239
+742% +$8.1M 0.01% 1062
2024
Q1 		$1.23M Buy
+32,397
New +$939K ﹤0.01% 1704

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Balyasny Asset Management's SYRE Position: Q2 2026 in Review

Balyasny Asset Management increased its Spyre Therapeutics (SYRE) stake by 165% in Q2 2026, buying an estimated $6.68M and bringing the position to 147,042 shares worth $13.1M. The position accounts for 0.02% of the portfolio, ranked #938.

Balyasny Asset Management first reported a position in SYRE in Q1 2024 and has held it in 6 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Balyasny Asset Management held 147,042 shares of Spyre Therapeutics worth $13.1M as of Q2 2026.
  • Balyasny Asset Management bought 91,565 Spyre Therapeutics shares in Q2 2026, an estimated $6.68M.
  • Spyre Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q2 2026, its #938 holding.
  • Balyasny Asset Management first reported a position in Spyre Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.